ArticleTherapeutic advances in urology
Leveraging MRI to reduce overtreatment in low‑grade prostate cancer: a retrospective single‑centre cohort study.
Article in Therapeutic advances in urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer is one of the most common malignancies in men worldwide. Radical prostatectomy is an effective curative treatment, but a noticeable number of men are ultimately found to have clinically insignificant disease, such as a Gleason score of 3 plus 3, on final histopathology. This suggests that some patients may undergo unnecessary surgery. The widespread adoption of multiparametric MRI has improved tumour detection and targeted biopsy accuracy, yet its potential role in preventing overtreatment is not fully understood. Because some low-risk tumours demonstrate low conspicuity on MRI, we hypothesised that specific MRI features, particularly low lesion conspicuity and PI-RADS 3 or lower, may be associated with final Grade Group 1 pathology in men undergoing radical prostatectomy. Objectives: The purpose of this study was to assess whether pre-operative multiparametric MRI can help identify men with potentially indolent prostate cancer and reduce unnecessary radical prostatectomies. We focused on MRI features such as PI-RADS 3 or lower, low lesion conspicuity and overall imaging quality to see how strongly they relate to final Grade Group 1 in men who were selected for surgery. Design: Retrospective single-centre cohort study. Methods: We reviewed 400 consecutive men who underwent robot-assisted radical prostatectomy for presumed clinically significant prostate cancer. Final pathology identified 13 men with Grade Group 1 disease. Pre-operative mpMRI examinations were reassessed for PI-RADS category, lesion location, lesion conspicuity and overall image quality to determine whether imaging features were associated with low-risk pathology. Results: Analyses showed that certain MRI characteristics were frequently associated with Gleason 3 plus 3 pathology. Several patients who proceeded to surgery had inconspicuous, equivocal or low probability MRI lesions such as PI-RADS 2 or 3 that lacked features typically associated with clinically significant cancer. Recognising these signatures may refine patient selection and support broader use of active surveillance. Conclusion: Assessment of MRI appearance, lesion conspicuity and PI-RADS category may improve selection for surgery and reduce overtreatment. MRI-based identification of low-grade prostate cancer could help avoid unnecessary prostatectomies and the associated morbidity while preserving oncologic safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.